Biofil Chemicals & Pharmaceuticals Share Price
32.08+0.11 (+0.34%)
-26.03% past 1 Year
Biofil Chemicals & Pharmaceuticals Ltd.is engaged in the manufacturing of drugs in the area of anti-bacterial, analgesics/antipyretics, anti-malarial, anti-psychotics, anti asthmatic/bronchodilators, diuretics, tranquilizer/hypnotics, anti inflammatory, analgesic/antipyretics, anti inflammatory steroids and
Corporate filings & documents
Announcements
Pursuant to Regulation 30 44 and 47 of SEBI(LODR) Regulations 2015 and in compliance with Section 108 of the Companies Act 2013 read with rule 20 of Companies (Management and Administration) Rules 2014 we enclosed herewith extract of newspaper published on 28th August 2026 in Free Press Mumbai (English) Free Press Indore (English) and Choutha Sansar (Hindi) edition.
1 week agoPursuant to Regulation 30 44 and 47 of SEBI(LODR) Regulations 2015 and in compliance with Section 108 of the Companies Act 2013 read with rule 20 of Companies (Management and Administration) Rules 2014 we enclosed herewith extract of newspaper published on 28th August 2026 in Free Press Mumbai (English) Free Press Indore (English) and Choutha Sansar (Hindi) edition.
1 week agoInformation under Regulation 44 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 and Section 108 of the Companies Act 2013 regarding voting through electronic mode for the 41st Annual General Meeting scheduled to be held on Wednesday 23rd September 2026
1 week agoInformation under Regulation 44 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 and Section 108 of the Companies Act 2013 regarding voting through electronic mode for the 41st Annual General Meeting scheduled to be held on Wednesday 23rd September 2026
1 week agoIntimation for Dispatch of letter to those shareholders whose e-mail addresses are not registered with company/ registrar and share transfer agent/ depository participants
1 week agoIntimation for Dispatch of letter to those shareholders whose e-mail addresses are not registered with company/ registrar and share transfer agent/ depository participants
1 week agoSubmission of Integrated Annual Report for the Financial Year 2025-26 along with Notice convening the 41st Annual General Meeting as per Regulation 34 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015
1 week agoSubmission of Integrated Annual Report for the Financial Year 2025-26 along with Notice convening the 41st Annual General Meeting as per Regulation 34 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015
1 week agoSubmission of Notice of 41st AGM scheduled to be held on Wednesday 23rd September 2026 at 3:00 P.M. (IST) through video conferencing (VC)/ Other audio-visual means (OAVM)
1 week agoSubmission of Notice of 41st AGM scheduled to be held on Wednesday 23rd September 2026 at 3:00 P.M. (IST) through video conferencing (VC)/ Other audio-visual means (OAVM)
1 week agoNewspaper publication of Notice of 41st AGM through Video Conferencing (VC)/ Other Audio Visual Means (OAVM)
2 weeks agoNewspaper publication of Notice of 41st AGM through Video Conferencing (VC)/ Other Audio Visual Means (OAVM)
2 weeks agoSubmission of publication of Un-audited Financial Results in the Newspaper pursuant to Regulation 47 of SEBI (Listing Obligation and Disclosure Requirement) Regulations 2015
3 weeks agoSubmission of publication of Un-audited Financial Results in the Newspaper pursuant to Regulation 47 of SEBI (Listing Obligation and Disclosure Requirement) Regulations 2015
3 weeks agoContinuation of Directorship of Mr. Ashok Kumar Ramawat (DIN: 08818263) as a Non-executive Independent Director of the company notwithstanding his attaining the age of 75 (Seventy Five )Years
3 weeks agoContinuation of Directorship of Mr. Ashok Kumar Ramawat (DIN: 08818263) as a Non-executive Independent Director of the company notwithstanding his attaining the age of 75 (Seventy Five )Years
3 weeks agoUn-Audited Financial Results for the quarter ended 30th June 2026
3 weeks agoUn-Audited Financial Results for the quarter ended 30th June 2026
3 weeks agoOutcome of Board Meeting held on Tuesday 11th August 2026 pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.
3 weeks agoOutcome of Board Meeting held on Tuesday 11th August 2026 pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.
3 weeks agoBiofil Chemicals & Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2026 inter alia to consider and approve the Un-Audited Financial Results of the Company for the first Quarter ended on 30th June 2026 along with Limited Review Report thereon. 2. To consider other routine matters with the permission of the chair.
1 month agoBiofil Chemicals & Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2026 inter alia to consider and approve the Un-Audited Financial Results of the Company for the first Quarter ended on 30th June 2026 along with Limited Review Report thereon. 2. To consider other routine matters with the permission of the chair.
1 month agoCertificate under Regulation 74(5) of the Securities and Exchange Board of India (Depository and Participants) Regulations 2018 for the quarter ended 30th June 2026.
2 months agoCertificate under Regulation 74(5) of the Securities and Exchange Board of India (Depository and Participants) Regulations 2018 for the quarter ended 30th June 2026.
2 months agoClosure of Trading Window for the quarter ended 30.06.2026
2 months agoClosure of Trading Window for the quarter ended 30.06.2026
2 months agoSubmission of publication of Audited Financial Results in the Newspaper pursuant to Regulation 47 of SEBI (Listing Obligation and Disclosure Requirement) Regulations 2015
3 months agoSubmission of publication of Audited Financial Results in the Newspaper pursuant to Regulation 47 of SEBI (Listing Obligation and Disclosure Requirement) Regulations 2015
3 months agoAudited Financial Result for the Financial Year ended 31.03.2026
3 months agoOutcome of Board Meeting held on Saturday 30th May 2026 pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.
3 months agoOutcome of Board Meeting held on Saturday 30th May 2026 pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.
3 months agoSubmission of Annual Secretarial Compliance Report for the Financial year ended 31st March 2026
3 months agoSubmission of Annual Secretarial Compliance Report for the Financial year ended 31st March 2026
3 months agoBiofil Chemicals & Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 inter alia to consider and approve the Audited Financial Results of the Company for the fourth Quarter as well as Financial Year ended on 31st March 2026.
3 months agoBiofil Chemicals & Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 inter alia to consider and approve the Audited Financial Results of the Company for the fourth Quarter as well as Financial Year ended on 31st March 2026.
3 months agoThe Company hereby submit drafts intimation letter sent to holders of Physical shares of the company for updating PAN KYC Nomination and other details in accordance with applicable SEBI Circulars in terms of provisions of Reg.30 of SEBI (LODR) Regulations 2015 from time to time.
4 months ago<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Biofil Chemicals & Pharmaceuticals Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L24233MP1985PLC002709</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>0.02</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>NA</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: Apoorv Jain <br/> Designation: Company Secretary and Compliance Officer <br/> EmailId: [email protected]</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: Pavan Singh Rajput <br/> Designation: Chief Financial Officer <br/> EmailId: [email protected]</div> </div> <div> <br/> Date: 10/04/2026<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>
4 months ago<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Biofil Chemicals & Pharmaceuticals Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L24233MP1985PLC002709</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>0.02</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>NA</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: Apoorv Jain <br/> Designation: Company Secretary and Compliance Officer <br/> EmailId: [email protected]</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: Pavan Singh Rajput <br/> Designation: Chief Financial Officer <br/> EmailId: [email protected]</div> </div> <div> <br/> Date: 10/04/2026<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>
4 months agoSubmission of Publication in Newspaper pursuant to SEBI circular for Special Window for Transfer and Dematerialisation of Physcial Securities.
5 months agoSubmission of Publication in Newspaper pursuant to SEBI circular for Special Window for Transfer and Dematerialisation of Physcial Securities.
5 months agoIntimation regarding SEBI Circular dated January 30 2026-Ease of Doing Investment- Special Window for Transfer and Dematerilaisation of Physical Securities .
5 months agoIntimation regarding SEBI Circular dated January 30 2026-Ease of Doing Investment- Special Window for Transfer and Dematerilaisation of Physical Securities .
5 months agoCertificate under Regulation 74(5) of the Securities and Exchange Board of India (Depository and Participants) Regulations 2018 for the quarter ended on 31st March 2026
5 months agoClosure of Trading Window period for the quarter and financial year ended 31.03.2026
5 months agoClosure of Trading Window period for the quarter and financial year ended 31.03.2026
5 months agoSubmission of Publication of Un-audited Financial Results for the quarter and nine months ended on 31st December 2025 in the newspaper pursuant to Regulation 47 of SEBI( Listing Obligation and Disclosure Requirement ) Regulations 2015
6 months agoSubmission of Publication of Un-audited Financial Results for the quarter and nine months ended on 31st December 2025 in the newspaper pursuant to Regulation 47 of SEBI( Listing Obligation and Disclosure Requirement ) Regulations 2015
6 months agoUn-Audited Financial Results of the Company for the quarter and nine month ended on 31st December 2025
6 months agoOutcome of Board Meeting held on Friday 13th February 2026
6 months agoOutcome of Board Meeting held on Friday 13th February 2026
6 months agoAnnual reports
Concalls & investor presentations
No presentations found
Corporate Actions
Date
Type
Details
No data available.
Company details
Registered office
12 / B Pologround Indore Madhya Pradesh PIN: 452015 Tel No: 0731-2723016 / 2426700 Fax No: 0731 2723017 / 2426700 Email: [email protected] Internet: www.biofilgroup.net
Registrars
Plot No. 60, Electronic Complex, Pardeshipura, Indore (M.P.)-452010 Plot No 60 Electronic Complex Pardeshipura PIN: Tel No: NULL Fax No: NULL Email: NULL
Management
Apoorv Jain, Company Secretary & Compliance Officer
Ketan Shah, Chairman & Managing Director
Ketan Shah, Chairman & Managing Director
Meet Shah, Non Independent & Non Executive Director
Ashok Kumar Ramawat, Non Executive Independent Director
Satish Beohar, Non Executive Independent Director
Gayatri Padiyar, Non Executive Independent Woman Director
Smitesh Shah, Non Independent & Non Executive Director
Details
BSE 524396
NSE BIOFILCHEM
ISIN INE829A01014